Reference
  1. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  2. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
  3. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
  4. Velcheti V, Kim ES, et al. Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): interim B-F1RST results. J Clin Oncol 2018;36(15_suppl): 12001–01.
  5. Hellmann MD, Ciuleanu TE, et al. Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden. N Engl J Med . 2018;378(22):2093–104.
  6. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 Apr 2;6(269)
  7. Robert M. Samstein. Et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet.2019 Feb;51(2):202-206.
  8. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1
therapy in metastatic melanoma. Cell. 2016 Mar 24;165(1):35-44.
  1. Hellmann M D, Ciuleanu T, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.The New England Journal of Medicine , 2018, 378(22): 2093-2104.
  2. Snyder A, Makarov V, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371: 2189-99.
  3. Carbone DP, Reck M, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017;376: 2415-26.
  4. Hellmann MD, Callahan MK, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 2018;33: 853-61 e4.
  5. Rosenberg JE, Hoffman-Censits J, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387: 1909-20.
  6. Bojovic, B. & Crowe, D. L. Dysfunctional telomeres promote genomic instability and metastasis in the absence of telomerase activity in oncogene induced mammary cancer. Mol. Carcinogen. 2013 Feb;52(2):103-17.
  7. Vermaat, J. S. et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin. Cancer Res. 2012 Feb 1;18(3):688-99.
  8. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010 Oct 28;467(7319):1114-7.
  9. Roschke, A. et al. Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin
maintenance. Neoplasia. 2008 Nov;10(11):1222-30.
  1. Hong, M. K. H. et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun.2015 Apr 1;6:6605.
  2. Brastianos, P. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015 Nov;5(11):1164-1177.
  3. Rooney, M. S., Shukla, S. A., et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity.Cell. 2015 Jan 15;160(1-2):48-61.
  4. Balachandran, V. P. et al. Identifcation of unique neoantigen qualities in long-term survivors of pancreatic cancer. 2017 Nov 23;551(7681):512-516.
  5. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012 Jun 28;366(26):2443-54.
  6. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science, 2016 Mar 25;351(6280):1463-9.